Kezar Life Sciences Analyst Ratings
Kezar Life Sciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 175.86% | Wells Fargo | $4 → $2 | Maintains | Equal-Weight |
| 10/12/2023 | 2658.62% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 10/05/2023 | — | JonesTrading | Downgrades | Buy → Hold | |
| 09/25/2023 | 2658.62% | HC Wainwright & Co. | $18 → $20 | Maintains | Buy |
| 08/11/2023 | — | Wells Fargo | Downgrades | Overweight → Equal-Weight | |
| 08/11/2023 | 2382.76% | HC Wainwright & Co. | $19 → $18 | Maintains | Buy |
| 05/12/2023 | 2520.69% | HC Wainwright & Co. | $21 → $19 | Maintains | Buy |
| 05/12/2023 | 1693.1% | Wells Fargo | $14 → $13 | Maintains | Overweight |
| 03/16/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 03/16/2023 | 2796.55% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 01/03/2023 | 1831.03% | Wells Fargo | $17 → $14 | Maintains | Overweight |
| 08/12/2022 | 2796.55% | HC Wainwright & Co. | $20 → $21 | Maintains | Buy |
| 06/28/2022 | 2244.83% | Wells Fargo | $13 → $17 | Maintains | Overweight |
| 05/13/2022 | 1693.1% | Wells Fargo | $14 → $13 | Maintains | Overweight |
| 05/04/2022 | 1831.03% | Wells Fargo | $19 → $14 | Maintains | Overweight |
| 03/18/2022 | 2934.48% | HC Wainwright & Co. | $20 → $22 | Maintains | Buy |
| 12/08/2021 | 2520.69% | Wells Fargo | → $19 | Initiates Coverage On | → Overweight |
| 11/16/2021 | 2658.62% | HC Wainwright & Co. | $12 → $20 | Maintains | Buy |
| 07/20/2021 | 1831.03% | JonesTrading | → $14 | Initiates Coverage On | → Buy |
| 06/04/2020 | 1555.17% | HC Wainwright & Co. | $9 → $12 | Maintains | Buy |
| 05/05/2020 | 1141.38% | HC Wainwright & Co. | $15 → $9 | Reiterates | → Buy |
| 03/13/2020 | 2382.76% | Wells Fargo | $30 → $18 | Maintains | Overweight |
| 07/29/2019 | 1968.97% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/14/2023 | 175.86% | 富国银行 | 4 美元 → 2 美元 | 维护 | 重量相等 |
| 2023 年 12 月 10 日 | 2658.62% | HC Wainwright & Co. | → 20 美元 | 重申 | 购买 → 购买 |
| 10/05/2023 | — | JonesTrading | 降级 | 买入 → 持有 | |
| 09/25/2023 | 2658.62% | HC Wainwright & Co. | 18 美元 → 20 美元 | 维护 | 买 |
| 08/11/2023 | — | 富国银行 | 降级 | 超重 → 重量相等 | |
| 08/11/2023 | 2382.76% | HC Wainwright & Co. | 19 美元 → 18 美元 | 维护 | 买 |
| 05/12/2023 | 2520.69% | HC Wainwright & Co. | 21 美元 → 19 美元 | 维护 | 买 |
| 05/12/2023 | 1693.1% | 富国银行 | 14 美元 → 13 美元 | 维护 | 超重 |
| 03/16/2023 | — | 威廉布莱尔 | 降级 | 跑赢大盘 → 市场表现 | |
| 03/16/2023 | 2796.55% | HC Wainwright & Co. | → 21 美元 | 重申 | → 购买 |
| 01/03/2023 | 1831.03% | 富国银行 | 17 美元 → 14 美元 | 维护 | 超重 |
| 2022 年 12 月 8 日 | 2796.55% | HC Wainwright & Co. | 20 美元 → 21 美元 | 维护 | 买 |
| 06/28/2022 | 2244.83% | 富国银行 | 13 美元 → 17 美元 | 维护 | 超重 |
| 05/13/2022 | 1693.1% | 富国银行 | 14 美元 → 13 美元 | 维护 | 超重 |
| 05/04/2022 | 1831.03% | 富国银行 | 19 美元 → 14 美元 | 维护 | 超重 |
| 03/18/2022 | 2934.48% | HC Wainwright & Co. | 20 美元 → 22 美元 | 维护 | 买 |
| 2021 年 8 月 12 日 | 2520.69% | 富国银行 | → 19 美元 | 启动覆盖范围开启 | → 超重 |
| 11/16/2021 | 2658.62% | HC Wainwright & Co. | 12 美元 → 20 美元 | 维护 | 买 |
| 2021 年 7 月 20 日 | 1831.03% | JonesTrading | → 14 美元 | 启动覆盖范围开启 | → 购买 |
| 06/04/2020 | 1555.17% | HC Wainwright & Co. | 9 美元 → 12 美元 | 维护 | 买 |
| 05/05/2020 | 1141.38% | HC Wainwright & Co. | 15 美元 → 9 美元 | 重申 | → 购买 |
| 03/13/2020 | 2382.76% | 富国银行 | 30 美元 → 18 美元 | 维护 | 超重 |
| 07/29/2019 | 1968.97% | HC Wainwright & Co. | → 15 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Kezar Life Sciences (KZR)?
Kezar Life Sciences (KZR) 的目标价格是多少？
The latest price target for Kezar Life Sciences (NASDAQ: KZR) was reported by Wells Fargo on November 14, 2023. The analyst firm set a price target for $2.00 expecting KZR to rise to within 12 months (a possible 175.86% upside). 11 analyst firms have reported ratings in the last year.
富国银行于2023年11月14日公布了Kezar Life Sciences（纳斯达克股票代码：KZR）的最新目标股价。该分析公司将目标股价定为2.00美元，预计KZR将在12个月内升至12个月内（可能上涨175.86％）。去年有11家分析公司公布了评级。
What is the most recent analyst rating for Kezar Life Sciences (KZR)?
Kezar Life Sciences（KZR）的最新分析师评级是多少？
The latest analyst rating for Kezar Life Sciences (NASDAQ: KZR) was provided by Wells Fargo, and Kezar Life Sciences maintained their equal-weight rating.
富国银行对Kezar Life Sciences（纳斯达克股票代码：KZR）的最新分析师评级由富国银行提供，Kezar Life Sciences维持同等权重评级。
When is the next analyst rating going to be posted or updated for Kezar Life Sciences (KZR)?
Kezar Life Sciences（KZR）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kezar Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kezar Life Sciences was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Kezar Life Sciences的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Kezar Life Sciences的最新评级是在2023年11月14日发布的，因此您应该预计下一个评级将在2024年11月14日左右公布。
Is the Analyst Rating Kezar Life Sciences (KZR) correct?
分析师对 Kezar Life Sciences (KZR) 的评级正确吗？
While ratings are subjective and will change, the latest Kezar Life Sciences (KZR) rating was a maintained with a price target of $4.00 to $2.00. The current price Kezar Life Sciences (KZR) is trading at is $0.73, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Kezar Life Sciences（KZR）评级维持不变，目标股价为4.00美元至2.00美元。Kezar Life Sciences（KZR）目前的交易价格为0.73美元，超出了分析师的预期区间。